Grants for Independent school districts - Federal

This funding opportunity supports researchers in conducting observational studies or validating biomarkers related to dental, oral, and craniofacial diseases, aiming to improve prevention, diagnosis, and treatment through prospective data collection and analysis.

This funding opportunity provides financial support for research consortia focused on improving the diagnosis and treatment of rare diseases through collaborative, patient-centered clinical studies involving multiple institutions and patient advocacy groups.

The "Enhancing NIDCD's Extramural Workforce Diversity through Research Experiences" grant aims to fund educational activities that inspire individuals from diverse and underrepresented backgrounds to pursue careers or further studies in biomedical and behavioral sciences research.

This funding opportunity supports innovative research projects that aim to improve health outcomes and promote health equity in the U.S. by addressing social determinants of health and enhancing healthcare delivery systems.

This funding opportunity supports researchers in analyzing existing data from a major study on adolescent brain development and health to uncover new insights and address health disparities among youth.

This funding opportunity supports the development of innovative tools and methodologies to study the human virome, inviting a diverse range of organizations to enhance our understanding of how viruses impact human health and disease.

The "Neuropathological Interactions Between COVID-19 and ADRD" grant aims to fund research that investigates how COVID-19 affects the brain and cognitive outcomes in models with Alzheimer's Disease and related dementias (AD/ADRD), how it accelerates these conditions in early stages, and how it potentially increases the risk for future AD/ADRD.

The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement. The proposed work directly supports the U.S. FDAs stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities. In addition to the work outlined above, the award recipient will assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.

This grant provides funding for innovative cancer research projects that address the unique health needs of military personnel, veterans, and their families, focusing on specific cancer types and strategic goals related to prevention, diagnosis, treatment, and survivorship.

This funding opportunity supports a variety of organizations in conducting research and restoration projects that improve fish and wildlife resources in the Great Lakes Basin.

This grant provides funding for researchers and institutions to develop innovative technologies that can record and modulate neural activity, with a focus on advancing neuroscience through proof-of-concept projects.

The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Substance Use Disorders (SUD). The COA development plan is expected to progress into the FDA drug development tool qualification program. This notice of funding opportunity (NOFO) utilizes the UG3/UH3Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases. The applications responding to this NOFO should contain a COA development plan that will cover both UG3 and UH3 phases. In the first 2-year UG3 phasethe project must have a set of operational milestones to be completed by the end of this period. Once NIDA program has evaluated the progress of the UG3 phase and determined that the UG3 phase has been successfully completed, it transitions to the UH3 phase to be funded for three additional years.The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug development tool (DDT) in the context of use (COI) of a SUD. Achieving this goal will greatly facilitate the development of treatments for SUDs. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

This funding opportunity supports research institutions and organizations in developing innovative technologies to study how neural cell groups in rodents respond to addictive substances, aiming to deepen our understanding of addiction-related behaviors.

This funding opportunity supports innovative research on new screening methods and treatments for severe conditions detectable in newborns, aimed at improving early detection and health outcomes.

This grant provides funding for institutional research training programs to develop skilled neuroscientists through comprehensive training in research, statistics, and communication, specifically targeting advanced graduate students and postdoctoral fellows.

This funding opportunity supports researchers in developing innovative theories and methods to better understand the complex interactions of genetic and non-genetic factors influencing human traits, particularly in relation to health and cancer risk.

The grant titled "Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Data Coordinating Center (Collaborative U24 Trial Required)" is aimed at funding the development and implementation of a Data Coordinating Center to manage data, provide statistical support, and ensure overall coordination for a multi-site clinical trial focused on preventing cardiovascular disease in young adults at high risk, while also promoting community engagement, diversity, and health equity.

The "Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults" grant aims to fund a network of clinical trials that will study the safety and potential effectiveness of psychedelic drugs in treating chronic pain in older adults, with a focus on those aged 75 and above.

This funding opportunity supports the development of research resources and community engagement initiatives to improve outcomes for individuals affected by rare cancers, requiring active involvement from patient advocates throughout the project.

This funding opportunity supports innovative research teams using non-human animal models to develop advanced methods for measuring and analyzing behavior in relation to environmental factors.